Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0MV3Q
|
||||
| Former ID |
DCL000711
|
||||
| Drug Name |
Axovan-3
|
||||
| Indication | Eating disorder; Obesity [ICD9: 278, 307.5; ICD10:E66, F50] | Discontinued in Phase 1 | [1] | ||
| Company |
Axovan AG
|
||||
| Target and Pathway | |||||
| Target(s) | Neuropeptide Y receptor 5 | Target Info | Antagonist | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.